Etelcalcetide Hydrochloride

CHEMBL3545183 Phase 4 Approved Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1084.7 g/mol
LogP
Phase
4

The hydrochloride salt form of etelcalcetide, this calcimimetic medication activates calcium receptors on parathyroid gland cells to reduce excess parathyroid hormone in dialysis patients. The salt form is used in the injectable formulation.

Molecular Weight

1084.7000 g/mol

TPSA

618.00 Ų

Therapeutic Areas

Mechanism of Action

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O.Cl

InChI

InChI=1S/C38H73N21O10S2.ClH/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69;/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52);1H/t18-,19-,21+,22-,23-,24-,25-,26-;/m1./s1

Molecular Formula

C38H74ClN21O10S2

HBD / HBA

19 / 17

Rotatable Bonds

36

Heavy Atoms

72

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The hydrochloride salt form of etelcalcetide, this calcimimetic medication activates calcium receptors on parathyroid gland cells to reduce excess parathyroid hormone in dialysis patients. The salt form is used in the injectable formulation.

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Yes, Etelcalcetide Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545183. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71515466. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.